accolade logo

Accolade welcomes Cindy R. Kent to its Board of Directors

By Accolade | January 27, 2021

Accolade Welcomes Cindy R. Kent to its Board of Directors

Business leader, healthcare executive and one of Savoy Magazine’s 2020 leading executives is driving positive change for the healthcare experience in the U.S.

SEATTLE – January 27, 2021 – Accolade (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate and utilize the healthcare system and their workplace benefits, today announced Cindy R. Kent, executive vice president and president of senior living of Brookdale Senior Living and former president and general manager of the 3M Infection Prevention Division, is joining its board of directors, effective immediately.  

“We are thrilled to have Cindy Kent join our board of directors. Her extensive experience in leading healthcare and business operations will enrich our board and provide actionable insight for our management team,” says Rajeev Singh, Accolade CEO.  “Cindy is a widely respected business leader and her experiences and background will complement our board as Accolade continues to grow and scale our services for new members and markets.”   

As an industry veteran in healthcare, Kent is the current executive vice president and president of senior living of Brookdale Senior Living, America’s largest senior living company with 700+ facilities across the U.S.  Brookdale is a $4.1B revenue business. Kent oversees day-to-day operations of senior living with responsibility for revenue and profitability growth. Prior to Brookdale, Kent oversaw the Infection Prevention Division at 3M, responsible for the $1.7B global business operations in 60 countries and sales in 170 countries. Kent’s management responsibility included clinical, research and development, supply chain operations and commercial functions globally. 

“I believe that Accolade is well positioned to have a transformative impact on healthcare and I am thrilled to join this esteemed board of directors and highly capable management team in this aim,” says Kent.  

Kent has been recognized by many outstanding organizations and publications for her pursuit of excellence, leadership capabilities and strategic thinking, including: Savoy Magazine’s “Most Influential Black Executives in Corporate America,” 2020; Black Enterprise Magazine’s “Top 100 Most Powerful Women in Business” 2017; “Top 35 Women Leaders in Healthcare” by the Women’s Health Leadership TRUST in 2014. She is a Henry Crown Fellow of The Aspen Institute.

Executive board leadership positions include Best Buy Co.’s Board of Directors, 2018 to 2020. She currently sits on the Board of Trust at Vanderbilt University.

Additional changes to Accolade’s Board of Directors include the departures of Michael Yang, managing partner at OMERS Ventures, and Jim Madden, co-founder and managing director of Carrick Capital Partners.   

“Both Michael Yang and Jim Madden have had a profound impact on Accolade,” says Singh. “I want to thank them for the incredible service and counsel they have provided as Accolade grew from a startup to a public company and established a new category of solutions on the healthcare landscape.”

About Accolade

Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Using a blend of cloud-based technologies, specialized support from Accolade Health Assistants® and Clinicians, and integrated data and programs across mobile, online and phone, Accolade navigates people through the healthcare system with trust, empathy and ease. Employers offer Accolade to employees and their families as the single place to turn for all health, healthcare, and benefits questions or concerns, increasing their engagement in benefits and connecting them to high-quality providers and care. By empowering members to make better decisions about their health, Accolade can support members in lowering the cost and complexity of healthcare while achieving consumer satisfaction ratings over 90 percent and an NPS of 60. For more information, visit Accolade on Twitter, Facebook, LinkedIn and at

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.  In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “likely,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key customers or partners; (v) the impact of COVID-19 on our business and results of operation; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our prospectuses filed with the SEC on July 1, 2020 and October 19, 2020, respectively, and our Quarterly Reports filed on Form 10-Q.  All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.